Skip to main content
Skip to content
Case File
efta-01355299DOJ Data Set 10Other

EFTA01355299

Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01355299
Pages
1
Persons
0
Integrity

Summary

Ask AI About This Document

0Share
PostReddit
Review This Document

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
GLDUS127 Annandale Capital SOF IV — Project Klein Exclusive deal Expected Glosing Date: June 2018 El Fund Secondary 11(GP-led Secondary K Single Asset Deal Seller type: Alternative funds Key investment data Transaction summary Invested Capital at dose E60-100m (US$80-120m) Number of companies 4 Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Business services / Healthcare services Use of leverage No Average age at purchase 9 years Description - Motivated quality GP aiming to recapitalize and extend their 2007 mid- market pan-European fund while providing liquidity to LPs - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital Investment rationale / Glendower Team angle Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capita! to exploit market dislocations Fot disci.m.sSon istaposes«..4y. The inwiatmant ~tamd agave I .W s. flot close-i. and the is no øuwantee tbal investinent w3E cwipleaeo,- forre pala og a kamre 'rivest-ed poitfo4m cx Mel g Al bu avaliatge 4,. after furt1wi due diligence.. prove surtable for :30F nr This slide hauld be reed and teine-wc-d in conjundion with the Important Information and "Important Performance Intornabon and • Notes to Investment Performance sections. Glendower Capital STRICTLY CONFIDENTIAL C0NFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0040352 CONFIDENTIAL SDNY_GM_00186536 EFTA01355299

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.